Lyrus Receives US FDA Approval for Critical UTI Treatment in the US
The U.S. Food and Drug Administration (FDA) has approved Lyrus Life Sciences’s Abbreviated New Drug Application (ANDA) for ‘Methenamine Hippurate Tablets USP, 1 gram’, an AB-rated, substitutable generic version of Hiprex® from Validus Pharmaceuticals LLC which is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered … Read more
